A combination of cisplatin, methotrexate, bleomycin, and vincristine (CABO) was assessed in advanced epidermoid head and neck cancer. Among 72 patients with recurrent or metastatic disease and measurable lesions, there were 9 complete and 27 partial responses for an overall response rate of 50%. The
Relations between histology, TNM-category and results of treatment with methotrexate-bleomycin-combination in squamous cell carcinomas of the oral cavity
β Scribed by Bitter, Klaus
- Book ID
- 122728717
- Publisher
- Elsevier Science
- Year
- 1973
- Weight
- 369 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0301-0503
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot
## Abstract A retrospective study was made of the correlation between preβoperative clinical or histologic findings and the prevalence of lymph node metastasis in 60 patients with squamous cell carcinoma of the oral cavity who had histologically confirmed neck metastasis. Of these 60 patients, 39 w